Skip to content

Author

Seth N. Sclair

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension.

BACKGROUND AND AIMS Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease with limited treatments and a need for glucocorticoid-sparing therapies. Zetomipzomib is a selective immunoproteasome inhibitor in development for AIH. APPROACH AND RESULTS PORTOLA was a randomized, double-blind, placebo-control...

Craig S. Lammert, Ethan M. Weinberg, Seth N. Sclair et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.